[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618601":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":25,"locations":34,"responsibleParty":45,"collaborators":25,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":25,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":25,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":71,"whyStopped":25,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"LG Chem","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence A","EXPERIMENTAL","Sequence A: Test drug -\\> Reference drug",[13,14],"Drug: Test drug: Fixed-dose combination (FDC) of gemigliptin\u002Fdapagliflozin\u002Fmetformin 50\u002F10\u002F1000 mg","Drug: Reference drug: gemigliptin (Zemiglo) 50mg, Xigduo XR 10\u002F1000 mg",{"label":16,"type":10,"description":17,"interventionNames":18},"Sequence B","Sequence B: Reference drug -\\> Test drug",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Test drug: Fixed-dose combination (FDC) of gemigliptin\u002Fdapagliflozin\u002Fmetformin 50\u002F10\u002F1000 mg","All participants take 1 tablet of either test drug or reference drug after meal.",[9,16],null,{"type":21,"name":27,"description":23,"armGroupLabels":28,"otherNames":25},"Reference drug: gemigliptin (Zemiglo) 50mg, Xigduo XR 10\u002F1000 mg",[9,16],[30],{"name":31,"affiliation":32,"role":33},"Kyung-Sang Yu, M.D., Professor","Seoul National University Hospital","PRINCIPAL_INVESTIGATOR",[35],{"facility":32,"status":25,"city":36,"state":25,"zip":37,"country":38,"countryCode":25,"cosmosGeoPoint":39,"geoPoint":44,"contacts":25},"Seoul","03080","South Korea",{"type":40,"coordinates":41},"Point",[42,43],126.9784,37.566,{"lat":43,"lon":42},{"type":46,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100618601","phase-1-a-clinical-study-to-see-how-the-body-handles-and-how-safe-a-combination-tablet-of-gemigliptin-dapagliflozin-and-metformin-50101000mg-is-compared-to-taking-gemigliptin-50mg-separately-with-dapagliflozinmetformin-101000mg-in-healthy-adults-after-a-meal-100618601",false,"NCT07333742","A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50\u002F10\u002F1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin\u002FMetformin 10\u002F1000mg in Healthy Adults After a Meal","A Randomized, Open Label, Single Oral Dose, 2x2 Crossover Study to Compare the Pharmacokinetics and Safety\u002FTolerability of Gemigliptin\u002FDapagliflozin\u002FMetformin 50\u002F10\u002F1000 mg and Coadministration of Gemigliptin 50 mg and Dapagliflozin\u002FMetformin 10\u002F1000 mg in Healthy Adults in Fed Condition","Inclusion Criteria:\n\n1. Age 19-50 years in healthy volunteers\n2. 18.0 kg\u002Fm\\^2 ≤ BMI ≤ 29.9 kg\u002Fm\\^2, 50kg ≤weight ≤ 90kg\n3. 60≤ FPG≤125 mg\u002FdL\n4. Subjects who voluntarily decides to participate in this clinical trial and agree in writing to ensure compliance with the clinical trial.\n\nExclusion Criteria:\n\n1. Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular system.\n2. Subjects with clinically significant abnormal findings during tests (or examinations)\n3. Subjects with a history of hypersensitivity or clinically significant hypersensitivity reactions to test drugs or other drugs\n4. Subjects judged ineligible by the investigator",true,"ALL","19 Years","50 Years",{"count":59,"type":60},50,"ACTUAL","INTERVENTIONAL",[63],"PHASE1","Bioequivalence study for the fixed-dose combination of gemigliptin\u002Fdapagliflozin\u002Fmetformin 50\u002F10\u002F1000 mg under fed conditions in healthy volunteers",[66,67],"Fed Conditions","Healthy Volunteer",[69,70],"Bioequivalence study","Fed condition","COMPLETED","2026-01-02",{"date":74,"type":60},"2026-01-12",{"date":76,"type":60},"2025-09-29",{"date":78,"type":60},"2025-11-27",{"name":5,"class":6},1]